Advances in silver nanoparticles and nanotechnology, which can realize sensitive diagnostic modalities, efficient medical treatment, and better prognosis as well as less adverse effects on non-target tissues, provide an amazing window in the field of cardiopulmonary diseases. The present investigation describes a green procedure for the in situ immobilizing silver nanoparticles over calcium lignosulfonate modified Fe3O4 magnetic nanoparticles mediated by Cydonia root extract (Fe3O4@lignosulfonate-Ag NPs) and its catalytic and subsequent biological performances. The characterization of synthesized Fe3O4@lignosulfonate-Ag NPs were analyzed using XRD, VSM, ICP, SEM, EdaX, elemental mapping and TEM. In the medicinal part of the present research, the lung (CCD-19Lu, WI-38, and BEAS-2B) and heart (HCASMC, HCAEC, and HPAEC) cell viability was determined by trypan blue assay. The caspase activity colorimetric assay kit and Rhodamine123 fluorescence dye were used to determine the caspase-3 activity and mitochondrial membrane potential, respectively. Apoptosis and DNA fragmentation were determined by the TUNEL test. In addition, the inflammatory cytokines concentrations were evaluated by the Rat inflammatory cytokine assay kit. Fe3O4@lignosulfonate-Ag NPs-treated cell cutlers decreased significantly (p ≤ 0.01) the caspase-3 activity, inflammatory cytokines concentrations, and DNA fragmentation, and enhanced the mitochondrial membrane potential and cell viability in the high concentration of Methotrexate-treated CCD-19Lu, WI-38, BEAS-2B, HCASMC, HCAEC, and HPAEC cells. In the antioxidant test, the IC50 of Fe3O4@lignosulfonate-Ag NPs and BHT against DPPH free radicals were 168 and 54 µg/mL, respectively. Finally, Fe3O4@lignosulfonate-Ag NPs may be used as a cardiopulmonary protective supplement to treat cardiopulmonary diseases.
Read full abstract